A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease (DeferipronPD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01539837
Recruitment Status : Unknown
Verified October 2012 by Imperial College London.
Recruitment status was:  Recruiting
First Posted : February 28, 2012
Last Update Posted : October 17, 2012
Information provided by (Responsible Party):
Imperial College London

Brief Summary:
Parkinson's disease (PD) is a common neurodegenerative disease affecting movement. Although drug treatments for PD are available they only treat the symptoms of the disease, fail to halt neuronal loss, and are associated with long term side effects and loss of efficacy. There is a chronic need to develop neuroprotective therapies. Increased iron and oxidative stress have been heavily implicated in the neurodegenerative process in PD, hence removal of excess iron by iron chelation represents a potential drug target. Iron chelators are extensively utilised to treat peripheral iron overload disorders (e.g. thalassaemia) and recently the investigators have demonstrated iron chelators such as Deferiprone can enter the brain removing excess iron and are neuroprotective in PD animal models. Although good tolerability and efficacy to remove brain iron has also been shown in a pilot study with the iron chelators Deferiprone in young patients with Friedreich Ataxia, where iron accumulates in the dentate nucleus, no studies have been conducted in aged individuals affected by PD. Hence the aims of this study are 1) to assess whether Deferiprone is well tolerated in PD patients, 2) whether Deferiprone can remove the excess iron levels found in the brain area affected by PD, the substantia nigra, as assessed by Magnetic resonance imaging (MRI) and 3) whether Deferiprone has any direct effect on the clinical symptoms of PD. Three groups of 12 (total 36) early stage drug free PD patients will be treated with 20 or 30mg/kg/d Deferiprone or Placebo for 6 months. Over the 6 months patients will receive serial MRI scans, neurological examinations not only to assess PD symptoms but also psychological state, plus blood test to monitor for potential side effects. Positive results from this pilot will help support larger clinical trials to evaluate whether Deferiprone can slow down/halt PD.

Condition or disease Intervention/treatment Phase
Parkinson's Disease Drug: Deferiprone Drug: Placebo Phase 2

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease
Study Start Date : February 2012
Estimated Primary Completion Date : September 2013
Estimated Study Completion Date : December 2013

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Placebo Comparator: A-Placebo
Drug excipient
Drug: Placebo
Feriprox placebo administered orally at the same dosing volume as the 20mg/kg/day feriprox per day
Other Name: Feriprox placebo
Active Comparator: B-Dferiprone
20mg/kg/day deferiprone
Drug: Deferiprone
20mg/kg/d or 30mg/kg/d Deferiprone divided into two equal doses (morning and evening), every day for 6 months
Other Name: Ferriprox
Active Comparator: C-Deferiprone
30mg/kg/day Deferiprone
Drug: Deferiprone
20mg/kg/d or 30mg/kg/d Deferiprone divided into two equal doses (morning and evening), every day for 6 months
Other Name: Ferriprox

Primary Outcome Measures :
  1. safety and efficacy [ Time Frame: 6 months ]
    To assess whether 6 month treatment with Deferiprone is well tolerated by PD patients and assess whether such treatment removes excess iron in the brain area affected in PD, the substantia nigra, as assessed by MRI.

Secondary Outcome Measures :
  1. Disease modification [ Time Frame: 6 months ]
    Assess whether Deferiprone therapy directly affects the symptoms of Parkinson's disease or other brain function e.g.psychological well being, during the course of the 6 months trial period

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   50 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical diagnosis of Parkinson's disease
  • disease duration less than 5 years
  • stable response to standard anti-Parkinson's medication for at least 6 weeks

Exclusion Criteria:

  • Other neurological conditions
  • Diabetes
  • Renal or liver disease
  • Blood disorders
  • Pregnancy or breast feeding
  • Conditions which cause immunocompromise e.g. episodes of neutropaenia or agranulocytosis, HIV etc
  • Prior history of hypersensitivity to Deferiprone or its excipient
  • Pacemaker
  • artificial heart valves
  • ever had surgery to the head
  • Metalic implants in the CNS e.g. cerebral aneurysm clips
  • history of metal entering the eye

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01539837

Contact: Antonio Martin-Bastida, MBBS +442075946685
Contact: Christina Kabba, BSc +442075946685

United Kingdom
Centre for Neuroscience, Imperial College London Recruiting
London, United Kingdom, W120NN
Contact: David T Dexter, PhD    +442075946665   
Principal Investigator: David T Dexter, PhD         
Sub-Investigator: Paola Piccini, MBBS, PhD         
Sub-Investigator: Ward Roberta, PhD         
Sub-Investigator: Rexford Newbold, PhD         
Sponsors and Collaborators
Imperial College London
Principal Investigator: David T Dexter, PhD Imperial College London

Responsible Party: Imperial College London Identifier: NCT01539837     History of Changes
Other Study ID Numbers: ICL-11/SC/0101
2011-001148-31 ( EudraCT Number )
11/SC/0101 ( Other Identifier: Research Ethics Committee )
First Posted: February 28, 2012    Key Record Dates
Last Update Posted: October 17, 2012
Last Verified: October 2012

Keywords provided by Imperial College London:
Parkinson's disease
Brain Iron
Iron chelation
Oxidative stress

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Chelating Agents
Trace Elements
Growth Substances
Physiological Effects of Drugs
Iron Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action